Analysts expect Crispr Theraptc (NASDAQ:CRSP) to post $2.05 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Crispr Theraptc’s earnings, with the highest sales estimate coming in at $3.60 million and the lowest estimate coming in at $500,000.00. Crispr Theraptc reported sales of $1.55 million in the same quarter last year, which would suggest a positive year over year growth rate of 32.3%. The company is expected to issue its next earnings results on Tuesday, November 28th.

On average, analysts expect that Crispr Theraptc will report full-year sales of $2.05 million for the current year, with estimates ranging from $7.30 million to $13.60 million. For the next fiscal year, analysts anticipate that the firm will post sales of $24.00 million per share. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for Crispr Theraptc.

Crispr Theraptc (NASDAQ:CRSP) last issued its earnings results on Thursday, August 10th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.06. Crispr Theraptc had a negative net margin of 406.61% and a negative return on equity of 47.46%. The business had revenue of $3.60 million during the quarter, compared to analysts’ expectations of $3.29 million. The company’s revenue was up 350.0% on a year-over-year basis.

CRSP has been the subject of several research analyst reports. Cann initiated coverage on shares of Crispr Theraptc in a report on Monday, July 17th. They issued a “market perform” rating for the company. Barclays PLC restated a “buy” rating and issued a $29.00 target price on shares of Crispr Theraptc in a report on Friday, September 8th. SunTrust Banks, Inc. initiated coverage on shares of Crispr Theraptc in a report on Thursday, July 13th. They issued a “hold” rating and a $16.00 target price for the company. Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Crispr Theraptc in a report on Tuesday, July 18th. Finally, Chardan Capital restated a “buy” rating on shares of Crispr Theraptc in a report on Monday, August 14th. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $23.08.

TRADEMARK VIOLATION WARNING: “$2.05 Million in Sales Expected for Crispr Theraptc (CRSP) This Quarter” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://www.watchlistnews.com/2-05-million-in-sales-expected-for-crispr-theraptc-crsp-this-quarter/1683126.html.

In related news, Director Kurt Von Emster sold 35,473 shares of the stock in a transaction on Tuesday, August 8th. The shares were sold at an average price of $18.63, for a total transaction of $660,861.99. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Samarth Kulkarni sold 27,154 shares of the stock in a transaction on Wednesday, August 30th. The stock was sold at an average price of $20.08, for a total transaction of $545,252.32. Following the sale, the insider now owns 110,893 shares of the company’s stock, valued at approximately $2,226,731.44. The disclosure for this sale can be found here. In the last quarter, insiders have sold 393,533 shares of company stock valued at $7,718,093. 39.98% of the stock is owned by company insiders.

Large investors have recently modified their holdings of the stock. Hershey Trust Co. acquired a new stake in Crispr Theraptc during the 3rd quarter worth $768,000. Credit Suisse AG acquired a new stake in Crispr Theraptc during the 1st quarter worth $1,742,000. Capital Investment Advisory Services LLC acquired a new stake in Crispr Theraptc during the 3rd quarter worth $193,000. Moloney Securities Asset Management LLC acquired a new stake in Crispr Theraptc during the 3rd quarter worth $235,000. Finally, ARK Investment Management LLC acquired a new stake in Crispr Theraptc during the 2nd quarter worth $206,000. Hedge funds and other institutional investors own 25.52% of the company’s stock.

Shares of Crispr Theraptc (CRSP) traded up $0.38 during trading on Friday, hitting $19.05. 258,555 shares of the stock traded hands, compared to its average volume of 198,224. Crispr Theraptc has a fifty-two week low of $11.63 and a fifty-two week high of $25.00.

About Crispr Theraptc

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Get a free copy of the Zacks research report on Crispr Theraptc (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Crispr Theraptc (NASDAQ:CRSP)

Receive News & Ratings for Crispr Theraptc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Theraptc and related companies with Analyst Ratings Network's FREE daily email newsletter.